The Zhitong Finance App learned that BOC International released a research report stating that it will raise the target price of Collumbotai Biotech (06990.HK) to HK$642 to maintain a “buy” rating. According to the bank, in the first half of the year, Collumbotai Biotech's product sales exceeded expectations, commercialization and R&D investment continued to accelerate, SAC-TMT fully advanced into the 1L NSCLC field, and the prototype for a new generation of conjugated drug matrices began to emerge.

The Zhitong Finance App learned that BOC International released a research report stating that it will raise the target price of Collumbotai Biotech (06990.HK) to HK$642 to maintain a “buy” rating. According to the bank, in the first half of the year, Collumbotai Biotech's product sales exceeded expectations, commercialization and R&D investment continued to accelerate, SAC-TMT fully advanced into the 1L NSCLC field, and the prototype for a new generation of conjugated drug matrices began to emerge.